Individual Patient Compassionate Use of Nirogacestat

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Overview

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Study Type

EXPANDED_ACCESS

Conditions

Desmoid Tumor NOTCH Gene Mutation Positive Tumors

Interventions

Nirogacestat (Gamma Secretase Inhibitor)DRUG

Patients will receive nirogacestat tablets to be taken orally.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. * Patient does not qualify to participate in an ongoing clinical trial.

Central Contacts

US Medical Information

CONTACT

888-275-7376 eMediUSA@emdserono.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.